Author: "Lippman S" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Lippman S"' showing total 559 results

Start Over Author "Lippman S"

559 results on '"Lippman S"'

1. Gender Norms and HIV Testing/Treatment Uptake: Evidence from a Large Population-Based Sample in South Africa

Author: Pulerwitz, J., Gottert, A., Kahn, K., Haberland, N., Julien, A., Selin, A., Twine, R., Peacock, D., Gómez-Olivé, X., Lippman, S. A., and Pettifor, A.
Published: 2019
Full Text: View/download PDF

2. Phase II study of fenretinide (N-[4-hydroxyphenyl]retinamide) in advanced breast cancer and melanoma.

Author: Modiano, M R, Dalton, W S, Lippman, S M, Joffe, L, Booth, A R, and Meyskens, F L, Jr
Subjects: Adult, Aged, Breast Neoplasms: drug therapy, Drug Evaluation, Female, Fenretinide, Humans, Male, Melanoma: drug therapy, Middle Aged, Tretinoin: analogs & derivatives, therapeutic use, toxicity, breast cancer, fenretinide, melanoma, retinoidsaminoglutethimide, fenretinide, tamoxifen, advanced cancer, article, breast cancer, cancer chemotherapy, clinical article, female, human, male, melanoma, night blindness, phase 2 clinical trial, priority journal, skin toxicity, Adult, Aged, Breast Neoplasms, Drug Evaluation, Female, Fenretinide, Human, Male, Melanoma, Middle Age, Support, Non-U.S. Gov't, Support, U.S. Gov't, P.H.S., Tretinoin
Abstract: Retinoids, the natural and synthetic analogs of vitamin A, are growth-inhibiting and differentiation-inducing agents and show clinical promise as chemopreventive and antineoplastic agents. Fenretinide, a new synthetic retinoid, has antitumor activity in certain in vitro and in vivo model systems and was relatively nontoxic in phase I trials. Based on these data, we designed a phase II study of Fenretinide involving 31 patients with advanced breast cancer [15] and melanoma [16], two cancers shown to be responsive to this agent in preclinical models. Fenretinide was inactive in patients with advanced disease. Toxicity was mild, and reversible. Mucocutaneous side effects occurred in 16 (52%) patients. Nyctalopia developed in three patients one of whom developed decreased B-wave amplitude of the scotopic electroretinogram. The minimal toxicity and significant activity in preclinical studies make this an attractive agent for future breast cancer chemoprevention studies.
Published: 1990

3. Retinoids and interferons: combination studies in human cancer

Author: Lotan, R., Clifford, J. L., Lippman, S. M., Azzi, Angelo, editor, Packer, Lester, editor, and Livrea, Maria A., editor
Published: 2000
Full Text: View/download PDF

4. Intraprostatic inflammation is positively associated with serum PSA in men with PSA <4 ng ml−1, normal DRE and negative for prostate cancer

Author: Umbehr, M H, Gurel, B, Murtola, T J, Sutcliffe, S, Peskoe, S B, Tangen, C M, Goodman, P J, Thompson, I M, Lippman, S M, Lucia, M S, Parnes, H L, Drake, C G, Nelson, W G, De Marzo, A M, and Platz, E A
Published: 2015
Full Text: View/download PDF

5. 1306P Early-stage pancreatic cancer detection using extracellular vesicles

Author: Sears, R., primary, Hinestrosa, J., additional, Schroeder, G., additional, Lewis, J., additional, Balcer, H., additional, Kurzrock, R., additional, Lippman, S., additional, Lowy, A., additional, and Billings, P., additional
Published: 2022
Full Text: View/download PDF

6. Das Zervixkarzinom. Gegenwärtiger Stand und neue Aspekte der systemischen Therapie

Author: Holdener, E. E., Massimini, G., Lippman, S., Bollag, W., Man, A., Bastert, G., editor, Wallwiener, D., editor, and Manth, S. M., editor
Published: 1994
Full Text: View/download PDF

7. Retinoid chemoprevention of aerodigestive carcinogenesis

Author: Hong, W. K., Lippman, S. M., Benner, S. E., Lee, J. S., Banzet, P., editor, Holland, J. F., editor, Khayat, D., editor, and Weil, M., editor
Published: 1994
Full Text: View/download PDF

8. Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancer

Author: Crew, K. D., Ho, K. A., Brown, P., Greenlee, H., Bevers, T. B., Arun, B., Sneige, N., Hudis, C., McArthur, H. L., Chang, J., Rimawi, M., Cornelison, T. L., Cardelli, J., Santella, R. M., Wang, A., Lippman, S. M., and Hershman, D. L.
Published: 2015
Full Text: View/download PDF

9. Uncertain Imitability: An Analysis of Interfirm Differences in Efficiency under Competition

Author: Lippman, S. A. and Rumelt, R. P.
Published: 1982
Full Text: View/download PDF

10. Inflammation-Related Genetic Variations and Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving First-Line Chemotherapy

Author: Pu, X, Hildebrandt, M AT, Lu, C, Roth, J A, Stewart, D J, Zhao, Y, Heist, R S, Ye, Y, Chang, D W, Su, L, Minna, J D, Lippman, S M, Spitz, M R, Christiani, D C, and Wu, X
Published: 2014
Full Text: View/download PDF

11. 15-Lipoxygenase-2 gene regulation by its product 15-(S)-hydroxyeicosatetraenoic acid through a negative feedback mechanism that involves peroxisome proliferator-activated receptor γ

Author: Subbarayan, V, Krieg, P, Hsi, L C, Kim, J, Yang, P, Sabichi, A L, Llansa, N, Mendoza, G, Logothetis, C J, Newman, R A, Lippman, S M, and Menter, D G
Published: 2006
Full Text: View/download PDF

12. Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity

Author: Zuo, X, Wu, Y, Morris, J S, Stimmel, J B, Leesnitzer, L M, Fischer, S M, Lippman, S M, and Shureiqi, I
Published: 2006
Full Text: View/download PDF

13. The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival

Author: William, W. N., Kim, J.-S., Liu, D. D., Solis, L., Behrens, C., Lee, J. J., Lippman, S. M., Kim, E. S., Hong, W. K., Wistuba, I. I., and Lee, H.-Y.
Published: 2012
Full Text: View/download PDF

14. Treatment of advanced squamous cell carcinoma of the head and neck with isotretinoin: a phase II randomized trial.

Author: Lippman, S M, Kessler, J F, Al-Sarraf, M, Alberts, D S, Itri, L M, Mattox, D, Von Hoff, D D, Loescher, L, and Meyskens, F L
Subjects: Adult, Aged, Carcinoma, Squamous Cell: drug therapy, pathology, Drug Evaluation, Female, Head and Neck Neoplasms: drug therapy, pathology, Humans, Isotretinoin, Male, Methotrexate: adverse effects, therapeutic use, Middle Aged, Random Allocation, Tretinoin: adverse effects, therapeutic use, head and neck cancer, retinoids, squamous cell carcinomaisotretinoin, methotrexate, advanced cancer, clinical article, female, head and neck carcinoma, human, intramuscular drug administration, male, phase 2 clinical trial, priority journal, squamous cell carcinoma, Adult, Aged, Carcinoma, Squamous Cell, Drug Evaluation, Female, Head and Neck Neoplasms, Human, Isotretinoin, Male, Methotrexate, Middle Age, Random Allocation, Support, Non-U.S. Gov't, Support, U.S. Gov't, P.H.S., Tretinoin
Abstract: Retinoids, the analogs of vitamin A, are active in vitro and in vivo against squamous cell carcinoma in animals and against certain epithelial precancers and cancers in humans. These data led us to design a prospective, multi-institutional, randomized phase II trial of isotretinoin in advanced head and neck squamous cell carcinoma. We randomly assigned 40 patients to receive isotretinoin or methotrexate, the best-studied and most active single agent for this disease. Overall, the study patients had extremely poor prognoses, i.e., low performance statuses and recurring disease after surgery and/or irradiation. Three objective responses (16%), including one complete response, occurred in the 19 evaluable isotretinoin-treated patients. Only one minor response (5%) occurred in the methotrexate-treated group. Toxicity occurred with both drugs, but was manageable and never life threatening in the retinoid group. These results and the established activity of retinoids in oral leukoplakia (a precursor of head and neck cancer) indicate the need for further study of this class of drugs in head and neck cancer.
Published: 1988

15. Retinoids as potential chemopreventive agents in squamous cell carcinoma of the head and neck.

Author: Lippman, S M, Garewal, H S, and Meyskens, F L, Jr
Subjects: Carcinoma, Squamous Cell: drug therapy, etiology, prevention & control, Clinical Trials as Topic, Head and Neck Neoplasms: drug therapy, etiology, prevention & control, Humans, Retinoids: pharmacology, therapeutic use, toxicity, etretinate, isotretinoin, retinoic acid, retinoid, cell transformation, conference paper, head cancer, human, leukoplakia, neck cancer, priority journal, risk factor, Carcinoma, Squamous Cell, Clinical Trials, Head and Neck Neoplasms, Human, Retinoids, Support, Non-U.S. Gov't, Support, U.S. Gov't, P.H.S.
Abstract: Although newer combined modality approaches, including neoadjuvant cytotoxic chemotherapy, for patients with squamous cell carcinoma (SCCA) of the head and neck have produced high initial complete response rates, they have not improved overall survival for patients with advanced disease. Vitamin A plays an essential role in the normal differentiation of epithelial tissues. Retinoids, analogs of vitamin A, are active in certain premalignant and malignant disorders including SCCA. Six studies, including one recently reported placebo-controlled randomized trial, have demonstrated the efficacy of retinoids in oral leukoplakia. Two studies (totalling 48 patients) have shown significant retinoid activity (67% overall complete response rate) in patients with aggressive, recurrent laryngeal papillomatosis. Two trials (including a randomized phase II trial) of isotretinoin in advanced, refractory SCCA of the head and neck have produced an objective response rate of 16%, which is comparable to that reported in single-agent studies with cytotoxic drugs. There is a need for further study of retinoids in head and neck cancer. The high initial response rates with current therapy and the high subsequent risks of local recurrence and of developing second primary tumors in head and neck cancer patients offer an excellent opportunity to investigate the use of retinoids as adjuvant therapy for this malignancy.
Published: 1989

16. Results of the use of vitamin A and retinoids in cutaneous malignancies.

Author: Lippman, S M and Meyskens, F L, Jr
Subjects: Animals, Etretinate: therapeutic use, Humans, Isotretinoin: therapeutic use, Keratosis: drug therapy, etiology, Mycosis Fungoides: drug therapy, Retinoids: therapeutic use, Skin Neoplasms: drug therapy, prevention & control, Vitamin A: therapeutic use, retinoid derivative, retinol, human, major clinical study, priority journal, review, skin cancer, skin carcinoma, skin precarcinoma, Animal, Etretinate, Human, Isotretinoin, Keratosis, Mycosis Fungoides, Retinoids, Skin Neoplasms, Support, Non-U.S. Gov't, Support, U.S. Gov't, P.H.S., Vitamin A
Published: 1989

17. Treatment of advanced squamous cell carcinoma of the skin with isotretinoin.

Author: Lippman, S M and Meyskens, F L, Jr
Subjects: Aged, Carcinoma, Squamous Cell: drug therapy, secondary, Combined Modality Therapy, Humans, Isotretinoin, Male, Middle Aged, Neoplasm Recurrence, Local: drug therapy, Skin Neoplasms: drug therapy, Tretinoin: therapeutic use, isotretinoin, cancer chemotherapy, case report, drug efficacy, human, skin carcinoma, squamous cell carcinoma, therapy, Aged, Carcinoma, Squamous Cell, Case Report, Combined Modality Therapy, Human, Isotretinoin, Male, Middle Age, Neoplasm Recurrence, Local, Skin Neoplasms, Support, Non-U.S. Gov't, Support, U.S. Gov't, P.H.S., Tretinoin
Abstract: To determine the efficacy of oral isotretinoin in refractory advanced squamous cell carcinoma of the skin.Case series trial.Tertiary care center at a university hospital.A consecutive collection of four patients with advanced squamous cell carcinoma of the skin who failed to respond to standard surgical or radiation therapy.Isotretinoin in gelatin capsules was given at a total daily dose of 1 mg/kg body weight in two divided doses for at least 4 weeks.Bidimensional tumor measurements at monthly intervals showed striking responses to isotretinoin in all four patients. Response durations ranged from 2 to more than 23 months. The drug produced reversible moderate mucocutaneous side effects and asymptomatic laboratory abnormalities.Impressive responses to isotretinoin occurred in our four patients and in six of ten other reported patients. Retinoic acid's mechanisms of action in cutaneous squamous cell carcinoma is not precisely known, but may involve the modulation of epidermal growth factor receptors and certain protein kinases. These in-vitro findings and the clinical data suggest that retinoids may be an effective and well-tolerated therapy for refractory advanced squamous cell carcinoma of the skin. The absence of any other effective systemic therapy indicates the need for continuing trials with retinoids in this disease.
Published: 1987

18. HOW WELL DO PATIENTS AND THEIR CARE PARTNERS UNDERSTAND RESULTS OF AMYLOID PET SCANS?

Author: Smith, Terrie Wetle, James R. Burke, Van Houtven C, Brenda L. Plassman, Emmanuelle Belanger, Lippman S, and Megan Shepherd-Banigan
Subjects: Abstracts, Health (social science), Text mining, business.industry, Medicine, Amyloid pet, Life-span and Life-course Studies, business, Bioinformatics, Health Professions (miscellaneous)
Abstract: The use of amyloid PET scans will likely become an integral part of the diagnostic evaluation for Alzheimer’s disease if Medicare approves reimbursement for the scans. Yet little is known about patients’ and their care partners’ understanding of the scan results. We will present findings addressing this question using both qualitative and quantitative data from CARE IDEAS. In this paper, we first examine the rate of agreement between scan results and patients’ and care partners’ understanding of the results. We then investigate the extent to which patient and care partner characteristics (diagnosis of dementia vs. mild cognitive impairment, severity of cognitive and functional impairment, age, education, gender and health literacy) explain differences in understanding of the scan results. Our findings may inform clinicians of factors to consider to optimize patients’ and family members’ level of understanding of results of amyloid PET scans.
Published: 2018

19. Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma

Author: Ikeda, S, Tsigelny, IF, Skjevik, AA, Kono, Y, Mendler, M, Kuo, A, Sicklick, JK, Heestand, G, Banks, KC, Talasaz, A, Lanman, RB, Lippman, S, and Kurzrock, R
Subjects: Adult, Male, Liver Cancer, Hepatocellular carcinoma, Oncology and Carcinogenesis, Circulating Tumor DNA, Rare Diseases, Clinical Research, Genetics, Humans, Prospective Studies, Oncology & Carcinogenesis, neoplasms, Next‐generation sequencing, Aged, Cancer, Tumor, Liquid biopsy, Liver Disease, Carcinoma, Human Genome, High-Throughput Nucleotide Sequencing, Hepatocellular, Middle Aged, Good Health and Well Being, Next-generation sequencing, Female, Digestive Diseases, Biomarkers
Abstract: BACKGROUND:Because imaging has a high sensitivity to diagnose hepatocellular carcinoma (HCC) and tissue biopsies carry risks such as bleeding, the latter are often not performed in HCC. Blood-derived circulating tumor DNA (ctDNA) analysis can identify somatic alterations, but its utility has not been characterized in HCC. MATERIALS AND METHODS:We evaluated 14 patients with advanced HCC (digital ctDNA sequencing [68 genes]). Mutant relative to wild-type allele fraction was calculated. RESULTS:All patients (100%) had somatic alterations (median = 3 alterations/patient [range, 1-8]); median mutant allele fraction, 0.29% (range, 0.1%-37.77%). Mutations were identified in several genes: TP53 (57% of patients), CTNNB1 (29%), PTEN (7%), CDKN2A (7%), ARID1A (7%), and MET (7%); amplifications, in CDK6 (14%), EGFR (14%), MYC (14%), BRAF (7%), RAF1 (7%), FGFR1 (7%), CCNE1 (7%), PIK3CA (7%), and ERBB2/HER2 (7%). Eleven patients (79%) had ≥1 theoretically actionable alteration. No two patients had identical genomic portfolios, suggesting the need for customized treatment. A patient with a CDKN2A-inactivating and a CTNNB1-activating mutation received matched treatment: palbociclib (CDK4/6 inhibitor) and celecoxib (COX-2/Wnt inhibitor); des-gamma-carboxy prothrombin level decreased by 84% at 2 months (1,410 to 242 ng/mL [normal: ≤7.4 ng/mL]; alpha fetoprotein [AFP] low at baseline). A patient with a PTEN-inactivating and a MET-activating mutation (an effect suggested by in silico molecular dynamic simulations) received sirolimus (mechanistic target of rapamycin inhibitor) and cabozantinib (MET inhibitor); AFP declined by 63% (8,320 to 3,045 ng/mL [normal: 0-15 ng/mL]). CONCLUSION:ctDNA derived from noninvasive blood tests can provide exploitable genomic profiles in patients with HCC. IMPLICATIONS FOR PRACTICE:This study reports that blood-derived circulating tumor DNA can provide therapeutically exploitable genomic profiles in hepatocellular cancer, a malignancy that is known to be difficult to biopsy.
Published: 2018
Full Text: View/download PDF

20. HIV self-screening distribution preferences and experiences among men who have sex with men in Mpumalanga Province: Informing policy for South Africa

Author: Radebe, O, primary, Lippman, S A, additional, Lane, T, additional, Gilmore, H, additional, Agnew, E, additional, Manyuchi, A, additional, and McIntyre, J A, additional
Published: 2019
Full Text: View/download PDF

21. Gender Equitable Men Scale--Revised

Author: Pulerwitz, J., primary, Gottert, A., additional, Kahn, K., additional, Haberland, N., additional, Julien, A., additional, Selin, A, additional, Twine, R., additional, Peacock, D., additional, Gómez‑Olivé, X., additional, Lippman, S. A., additional, and Pettifor, A., additional
Published: 2019
Full Text: View/download PDF

22. HOW WELL DO PATIENTS AND THEIR CARE PARTNERS UNDERSTAND RESULTS OF AMYLOID PET SCANS?

Author: Plassman, B L, primary, Van Houtven, C H, additional, Lippman, S, additional, Smith, V, additional, Burke, J R, additional, Shepherd-Banigan, M, additional, Belanger, E, additional, and Wetle, T, additional
Published: 2018
Full Text: View/download PDF

23. Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancer

Author: Crew, K. D., primary, Ho, K. A., additional, Brown, P., additional, Greenlee, H., additional, Bevers, T. B., additional, Arun, B., additional, Sneige, N., additional, Hudis, C., additional, McArthur, H. L., additional, Chang, J., additional, Rimawi, M., additional, Cornelison, T. L., additional, Cardelli, J., additional, Santella, R. M., additional, Wang, A., additional, Lippman, S. M., additional, and Hershman, D. L., additional
Published: 2014
Full Text: View/download PDF

24. P4.068 Hazardous Alcohol Consumption and Sexual Partner Concurrency Among Adults in Rural South Africa

Author: Lancaster, K, primary, Lippman, S, additional, Maman, S, additional, Kahn, K, additional, MacPhail, C, additional, and Pettifor, A, additional
Published: 2013
Full Text: View/download PDF

25. O421 NON‐PNEUMATIC ANTI‐SHOCK GARMENT (NASG) FOR OBSTETRIC HEMORRHAGE: HARARE, ZIMBABWE

Author: Magwali, T.L., primary, Butrick, E., additional, Mambo, V., additional, El Ayadi, A., additional, Lippman, S., additional, Bergel, E., additional, Gibbons, L., additional, Merialdi, M., additional, and Miller, S., additional
Published: 2012
Full Text: View/download PDF

26. O461 NON-PNEUMATIC ANTI-SHOCK GARMENT (NASG) DECREASES MATERNAL DEATHS IN LUSAKA, ZAMBIA

Author: Mkumba, G., primary, Butrick, E., additional, Amafumba, R., additional, McDonald, K., additional, DeMulder, J., additional, El Ayadi, A., additional, Lippman, S., additional, Gibbons, L., additional, Bergel, E., additional, Merialdi, M., additional, and Miller, S., additional
Published: 2012
Full Text: View/download PDF

27. L4.1 Evolution of Battle Trials at Md Anderson Cancer Center

Author: Hong, W.K., primary, Kim, E., additional, Herbst, R., additional, Papadimitrakopoulou, V., additional, Gold, K., additional, Wistuba, I., additional, Lee, J., additional, and Lippman, S., additional
Published: 2012
Full Text: View/download PDF

28. Lectures

Author: Doroshow, J., primary, Liu, E. T., additional, Pellini, M., additional, Miller, V., additional, Palmer, G., additional, Averbuch, S., additional, Green, G., additional, Novotny, J., additional, Paoletti, P., additional, Patel, K., additional, Hoos, A., additional, Gaynor, R., additional, Melemed, S., additional, Reinhard, C., additional, Teh, B. T., additional, Hong, W. K., additional, Kim, E., additional, Herbst, R., additional, Papadimitrakopoulou, V., additional, Gold, K., additional, Wistuba, I., additional, Lee, J., additional, Lippman, S., additional, Jackson, J. R., additional, Zitvogel, L., additional, Meisel, C., additional, Workman, P., additional, Dalton, W. S., additional, Botwood, N., additional, Davis, B. J., additional, Batist, G., additional, Assouline, S., additional, Camlioglu, E., additional, Tetu, B., additional, Spatz, A., additional, Diaz, Z., additional, Aguilar-Mahecha, A., additional, Basik, M., additional, Rodon, J., additional, Dienstmann, R., additional, Cortes, J., additional, Saura, C., additional, Aura, C., additional, Hernandez-Losa, J., additional, Vivancos, A., additional, Joan, J., additional, del Campo, J., additional, Felip, E., additional, Seoane, J., additional, Tabernero, J. T., additional, Friend, S. H., additional, Tsimberidou, A. M., additional, Hong, D. S., additional, Wheler, J. J., additional, Ye, Y., additional, Fu, S., additional, Piha-Paul, S. A., additional, Naing, A., additional, Falchook, G. S., additional, Janku, F., additional, Luthra, R., additional, Wen, S., additional, Kurzrock, R., additional, Naley, M., additional, Johnson, P., additional, Schuerer, K., additional, Lopes, M., additional, Hood, L. E., additional, Yarden, Y., additional, and Quackenbush, J., additional
Published: 2012
Full Text: View/download PDF

29. Effect Of Vitamin E And Selenium On F2-Isoprostanes, An Oxidative Stress Biomarker, And Lung Function

Author: Cassano, P A., primary, Guertin, Kristin A., additional, Kristal, Alan R., additional, Arnold, Katie B., additional, Crowley, J J., additional, Hartline, J A., additional, Goodman, P J., additional, Tangen, C M., additional, Minasian, L M., additional, Lippman, S M., additional, and Klein, E, additional
Published: 2012
Full Text: View/download PDF

30. No better than less expensive drugs

Author: Perry, T. L., primary, Lippman, S. S., additional, McConnell, M., additional, and Tejani, A. M., additional
Published: 2012
Full Text: View/download PDF

31. Prevalence and factors associated with HSV-2 and hepatitis B infections among truck drivers crossing the southern Brazilian border

Author: Pinho, A. A., primary, Chinaglia, M., additional, Lippman, S. A., additional, Reingold, A., additional, Diaz, R. S., additional, Sucupira, M. C., additional, Page, K., additional, and Diaz, J., additional
Published: 2011
Full Text: View/download PDF

32. P2-S3.05 Association of STI-related stigma and shame to STI testing and partner notification among young black men in San Francisco

Author: Lippman, S., primary, Morris, J., additional, Lightfoot, M., additional, and Philip, S., additional
Published: 2011
Full Text: View/download PDF

33. Do elderly chemorefractory NSCLC patients derive benefit from salvage targeted therapy? Subgroup analysis of clinical outcome and toxicity from the BATTLE trial.

Author: Tsao, A. S., primary, Liu, S., additional, Lee, J. J., additional, Alden, C. M., additional, Kim, E. S., additional, Blumenschein, G. R., additional, Herbst, R. S., additional, Lippman, S. M., additional, Wistuba, I. I., additional, and Hong, W. K., additional
Published: 2011
Full Text: View/download PDF

34. Biologic risk model for recurrence in resected early-stage non-small cell lung cancer (ES NSCLC).

Author: Gold, K. A., primary, Lee, J. J., additional, Ping, Y., additional, Behrens, C., additional, Liu, D., additional, Lee, H., additional, Koo, J. S., additional, Lotan, R., additional, Solis, L., additional, Rinsurongkawong, W., additional, Stewart, D. J., additional, Hofstetter, W. L., additional, Swisher, S., additional, Lippman, S. M., additional, Wistuba, I. I., additional, Hong, W. K., additional, and Kim, E. S., additional
Published: 2011
Full Text: View/download PDF

35. Updated clinical and biomarker results from a phase I study of vandetanib with radiation therapy (RT) with or without cisplatin in locally advanced head and neck squamous cell carcinoma (HNSCC).

Author: Papadimitrakopoulou, V., primary, Heymach, J., additional, Frank, S. J., additional, Myers, J., additional, Lin, H., additional, Tran, H. T., additional, Chen, C., additional, Hirsch, F. R., additional, Langmuir, P. B., additional, Vasselli, J. R., additional, Lippman, S. M., additional, and Raben, D., additional
Published: 2011
Full Text: View/download PDF

36. DNA methyltransferase-3B (DNMT3B) in oral cancer (OC) development.

Author: Saintigny, P., primary, Jelinek, J., additional, Pickering, C. R., additional, Lang, W., additional, Frederick, M. J., additional, Zhang, L., additional, Ren, H., additional, Papadimitrakopoulou, V., additional, Lee, J. J., additional, Kim, E. S., additional, Fan, Y. H., additional, El-Naggar, A. K., additional, Hong, W. K., additional, Myers, J., additional, Issa, J. J., additional, Lippman, S. M., additional, and Mao, L., additional
Published: 2011
Full Text: View/download PDF

37. Randomized trial of a short course of erlotinib 150 to 300 mg daily prior to surgery for squamous cell carcinomas of the head and neck (SCCHN) in current, former, and never smokers: Objective responses and clinical outcomes.

Author: William Junior, W. N., primary, Weber, R. S., additional, Lee, J. J., additional, Myers, J., additional, Ginsberg, L. E., additional, El-Naggar, A. K., additional, Sturgis, E. M., additional, Sabichi, A. L., additional, Kies, M. S., additional, Hanna, E. Y., additional, Hessel, A. C., additional, Lu, C., additional, Lai, S. Y., additional, Ayuste, R., additional, Lippman, S. M., additional, and Kim, E. S., additional
Published: 2011
Full Text: View/download PDF

38. Evaluation of Src Tyr419 as a predictive biomarker in a neoadjuvant trial using dasatinib in resectable malignant pleural mesothelioma.

Author: Tsao, A. S., primary, Wistuba, I. I., additional, Mehran, R. J., additional, Gil, J., additional, Nunez, M., additional, Lee, J., additional, Lin, H., additional, Lippman, S. M., additional, and Hong, W. K., additional
Published: 2010
Full Text: View/download PDF

39. Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF- 1R) and insulin receptor (IR) in patients with advanced solid tumors.

Author: Carden, C. P., primary, Kim, E. S., additional, Jones, R. L., additional, Alam, S. M., additional, Johnson, F. M., additional, Stephens, A. W., additional, Poondru, S., additional, Gedrich, R., additional, Lippman, S. M., additional, and Kaye, S. B., additional
Published: 2010
Full Text: View/download PDF

40. Gene expression profiling of oral preneoplastic lesions (OPL) from a prospective prevention trial.

Author: Saintigny, P., primary, Zhang, L., additional, El-Naggar, A. K., additional, Papadimitrakopoulou, V., additional, Feng, L., additional, Lee, J., additional, Kim, E. S., additional, Hong, W. K., additional, Lippman, S. M., additional, and Mao, L., additional
Published: 2010
Full Text: View/download PDF

41. Human papillomavirus (HPV) transmission from oropharyngeal cancer patients to sexual partners.

Author: Papadimitrakopoulou, V., primary, Guo, M., additional, Etzel, C., additional, Solomon, B., additional, Sturgis, E. M., additional, Lippman, S. M., additional, Hong, W. K., additional, and Tsao, A. S., additional
Published: 2010
Full Text: View/download PDF

42. Use of telomere length in peripheral leukocytes to predict risk of recurrence in patients with early-stage non-small cell lung cancer after curative resection.

Author: Kim, E. S., primary, Vaporciyan, A. A., additional, Xing, J., additional, Huang, M., additional, Spitz, M. R., additional, Lippman, S. M., additional, Gu, J., additional, Roth, J. A., additional, and Wu, X., additional
Published: 2010
Full Text: View/download PDF

43. Non-small cell lung cancer (NSCLC) in patients under 50: A long-term follow-up from the M. D. Anderson Cancer Center tumor registry.

Author: Johnson, E. D., primary, Hanneken, J. M., additional, Taylor, S. H., additional, Nunnelley, M. J., additional, Erasmus, J. J., additional, Swisher, S., additional, Gomez, D. R., additional, Lippman, S. M., additional, and Karp, D. D., additional
Published: 2010
Full Text: View/download PDF

44. Genetic variants in the telomere maintenance pathway as predictors of second primary tumors and recurrence of early-stage head and neck cancer.

Author: Chang, J. Y., primary, Lippman, S. M., additional, Lee, J., additional, Huang, M., additional, and Wu, X., additional
Published: 2010
Full Text: View/download PDF

45. A phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN).

Author: Sabichi, A. L., primary, Kies, M. S., additional, Glisson, B. S., additional, Lu, C., additional, Ginsberg, L. E., additional, Bartos, C. I., additional, Feng, L., additional, Tran, H. T., additional, Lippman, S. M., additional, and Blumenschein, G. R., additional
Published: 2010
Full Text: View/download PDF

46. Effect Of Vitamin E And Selenium On Incidence Of Physician-Diagnosed COPD: The Selenium And Vitamin E Cancer Prevention Trial (SELECT)

Author: Cassano, Patricia A., primary, Arnold, K B., additional, Guertin, K A., additional, Kristal, A R., additional, Crowley, J J., additional, Hartline, J, additional, Goodman, P J., additional, Tangen, C M., additional, Minasian, L M., additional, Lippman, S M., additional, Coltman, C A., additional, and Klein, E, additional
Published: 2010
Full Text: View/download PDF

47. Prevalence, distribution and correlates of endocervical human papillomavirus types in Brazilian women

Author: Lippman, S A, primary, Sucupira, M C A, additional, Jones, H E, additional, Luppi, C G, additional, Palefsky, J, additional, van de Wijgert, J H H M, additional, Oliveira, R L S, additional, and Diaz, R S, additional
Published: 2010
Full Text: View/download PDF

48. Serum dioxin concentrations and menstrual cycle characteristics

Author: Eskenazi, B, Warner, M, Mocarelli, P, Samuels, S, Needham, L, Patterson, D, Lippman, S, Vercellini, P, Gerthoux, P, Brambilla, P, Olive, D, Needham, LL, Patterson, DG, Gerthoux, PM, Olive, D., MOCARELLI, PAOLO, BRAMBILLA, PAOLO, Eskenazi, B, Warner, M, Mocarelli, P, Samuels, S, Needham, L, Patterson, D, Lippman, S, Vercellini, P, Gerthoux, P, Brambilla, P, Olive, D, Needham, LL, Patterson, DG, Gerthoux, PM, Olive, D., MOCARELLI, PAOLO, and BRAMBILLA, PAOLO
Abstract: 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a widespread industrial environmental contaminant. Animal studies suggest that TCDD exposure alters the estrus cycle. Twenty years after a 1976 industrial explosion in Seveso, Italy, the authors interviewed female residents to determine whether there was an association between TCDD exposure and current menstrual cycle characteristics. The authors analyzed serum samples collected soon after the explosion to quantify individual TCDD levels. Among women who were premenarcheal at the time of the explosion, a 10-fold increase in serum TCDD level was associated with a lengthening of the menstrual cycle by 0.93 days (95% confidence interval (Cl): -0.01, 1.86) and a reduction in the odds of scanty menstrual flow (adjusted odds ratio = 0.33, 95% Cl: 0.10, 1.06). However, among women who were postmenarcheal at the time of the explosion, TCDD was not associated with menstrual cycle length (adjusted beta = -0.03 days, 95% Cl: -0.61, 0.54) or scantiness of flow (adjusted odds ratio = 1.36, 95% Cl: 0.70, 2.64). In both menarche groups, TCDD levels were associated with decreased odds of having irregular cycles (adjusted odds ratio = 0.46, 95% Cl: 0.23, 0.95) but were not related to days of flow (adjusted P = 0.16 days, 95% Cl: -0.08, 0.41). These results are consistent with effects of TCDD on ovarian function noted in some animal species and with greater sensitivity to TCDD during development
Published: 2002

49. Phase I evaluation of vandetanib with radiation therapy (RT) ± cisplatin in previously untreated advanced head and neck squamous cell carcinoma (HNSCC)

Author: Papadimitrakopoulou, V., primary, Frank, S. J., additional, Blumenschein, G. R., additional, Chen, C., additional, Kane, M., additional, Cohen, E. E., additional, Langmuir, P., additional, Krebs, A. D., additional, Lippman, S. M., additional, and Raben, D., additional
Published: 2009
Full Text: View/download PDF

50. Phase I study of pemetrexed in recurrent/metastatic head and neck squamous cell cancer (HNSCC) and to assess the need for steroid premedication

Author: Coscio, A., primary, William, W. N., additional, Feng, L., additional, Glisson, B., additional, Ayuste, R., additional, Ginsberg, L., additional, Lee, J. J., additional, Obasaju, C., additional, Lippman, S. M., additional, and Kim, E. S., additional
Published: 2009
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

559 results on '"Lippman S"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources